EU/3/20/2329
Table of contents
About
On 21 August 2020, orphan designation EU/3/20/2329 was granted by the European Commission to YES Pharmaceutical Development Services GmbH, Germany, for infigratinib for the treatment of cholangiocarcinoma.
Key facts
Active substance |
Infigratinib
|
Disease / condition |
Treatment of cholangiocarcinoma
|
Date of first decision |
21/08/2020
|
Outcome |
Positive
|
EU designation number |
EU/3/20/2329
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
YES Pharmaceutical Development Services GmbH
Bahnstrasse 42-46
61381 Friedrichsdorf
Germany
Tel: +49 6172 764 64 65
E-mail: laura.boteanu-jotzu@pharmalex.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.